tiprankstipranks
Advertisement
Advertisement

JP:4502 Stock Latest News

Protagonist exercises right to opt out of 50:50 U.S. arrangement for rusfertide
The FlyProtagonist exercises right to opt out of 50:50 U.S. arrangement for rusfertide
2d ago
TAK
PTGX
Spyre Therapeutics price target raised to $80 from $65 at Wedbush
PremiumThe Fly
Spyre Therapeutics price target raised to $80 from $65 at Wedbush
17d ago
TAK
SYRE
Takeda upgraded to Outperform from Market Perform at Bernstein
PremiumThe Fly
Takeda upgraded to Outperform from Market Perform at Bernstein
22d ago
TAK
Denali Therapeutics regains full rights to DNL593
PremiumThe Fly
Denali Therapeutics regains full rights to DNL593
25d ago
TAK
DNLI
Abivax appoints Michael Nesrallah as chief commercial officer
PremiumThe Fly
Abivax appoints Michael Nesrallah as chief commercial officer
29d ago
TAK
ABVX
Axsome Therapeutics enters TAK-063 asset purchase agreement with Takeda
PremiumThe FlyAxsome Therapeutics enters TAK-063 asset purchase agreement with Takeda
29d ago
TAK
AXSM
Alumis shares should trade higher on ‘major success’ at AAD, says Ramond James
Premium
The Fly
Alumis shares should trade higher on ‘major success’ at AAD, says Ramond James
1M ago
JNJ
TAK
Alumis price target raised to $55 from $50 at Oppenheimer
Premium
The Fly
Alumis price target raised to $55 from $50 at Oppenheimer
1M ago
JNJ
TAK
Takeda’s Oral Psoriasis Drug Zasocitinib Shows Strong Phase 3 Results
PremiumCompany Announcements
Takeda’s Oral Psoriasis Drug Zasocitinib Shows Strong Phase 3 Results
1M ago
Takeda announces new data from Phase 3 studies of TAK-279
PremiumThe Fly
Takeda announces new data from Phase 3 studies of TAK-279
1M ago
TAK
Takeda Sets June CEO Handover to Julie Kim and Overhauls Board Line-up
PremiumCompany Announcements
Takeda Sets June CEO Handover to Julie Kim and Overhauls Board Line-up
1M ago
Takeda Unveils Cost-Saving Transformation to Fund Next Wave of Drug Launches
PremiumCompany Announcements
Takeda Unveils Cost-Saving Transformation to Fund Next Wave of Drug Launches
1M ago
Alkermes price target lowered to $43 from $45 at Piper Sandler
PremiumThe FlyAlkermes price target lowered to $43 from $45 at Piper Sandler
1M ago
TAK
ALKS
Protagonist Therapeutics price target raised to $100 from $86 at Wedbush
Premium
The Fly
Protagonist Therapeutics price target raised to $100 from $86 at Wedbush
2M ago
TAK
PTGX
Takeda, Protagonist announce FDA acceptance of rusfertide new drug application
Premium
The Fly
Takeda, Protagonist announce FDA acceptance of rusfertide new drug application
2M ago
TAK
PTGX
Takeda and Protagonist Win FDA Priority Review for First-in-Class Polycythemia Vera Drug
PremiumCompany Announcements
Takeda and Protagonist Win FDA Priority Review for First-in-Class Polycythemia Vera Drug
2M ago
Boston Scientific names Cathy Smith, Christophe Weber to board of directors
PremiumThe Fly
Boston Scientific names Cathy Smith, Christophe Weber to board of directors
2M ago
BSX
TAK
Takeda announces data from Phase 3 KEPLER trial of ENTYVIO
PremiumThe Fly
Takeda announces data from Phase 3 KEPLER trial of ENTYVIO
2M ago
TAK
Takeda granted Priority Review for oveporexton by FDA
PremiumThe Fly
Takeda granted Priority Review for oveporexton by FDA
3M ago
TAK
Takeda Wins FDA Priority Review for Potential First-in-Class Narcolepsy Drug
PremiumCompany AnnouncementsTakeda Wins FDA Priority Review for Potential First-in-Class Narcolepsy Drug
3M ago
Takeda raises FY25 core EPS view to 486 yen from 479 yen
Premium
The Fly
Takeda raises FY25 core EPS view to 486 yen from 479 yen
3M ago
TAK
Takeda reports Q3 core EPS 428 yen vs. 443 yen last year
Premium
The Fly
Takeda reports Q3 core EPS 428 yen vs. 443 yen last year
3M ago
TAK

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >